Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.

MAbs · 2026 · PMC13271273 · PMID 42271190

Europe PMC DOI

hedged sentence

0.1792

closest p · 3.6× alpha

0.1792

boldest claim

The sentences

did not reach statistical significancep = 0.1792not close (p > 0.1)

Notwithstanding, combination treatment of the HER2×CD2 bispecific and the 5 μg/kg dose of solitomab mediated meaningful tumor growth control, although the effect did not reach statistical significance ( p = 0.1792, Figure 5B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.